Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(11):883-884; doi:10.1093/jnci/djh159
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ponzone, R.
Right arrow Articles by Sismondi, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ponzone, R.
Right arrow Articles by Sismondi, P.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

Riccardo Ponzone, Nicoletta Biglia, Piero Sismondi

Affiliation of authors: Academic Department of Gynecological Oncology, Mauriziano Umberto I° Hospital and Institute for Cancer Research and Treatment of Candiolo, Turin, Italy

Correspondence to: Riccardo Ponzone, MD, PhD, Mauriziano Umberto I° Hospital, Largo Turati 62, 10128 Turin, Italy (e-mail: rponzone@mauriziano.it)

The first 10% of the full text of this article appears below.

Stearns et al. (1) provide convincing evidence on the influence of paroxetine, a selective serotonin reuptake inhibitor (SSRI), in the metabolic pathway of tamoxifen when administered to patients with breast cancer. In particular, they found that paroxetine decreased the plasma concentration of a metabolite they . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
Brooke Ratliff, Eric C. Dietze, Gregory R. Bean, Cassandra Moore, Sam Wanko, and Victoria L. Seewaldt
J Natl Cancer Inst 2004 96: 883. [Extract] [Full Text] [PDF]

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
Ernst A. Lien, Per M. Ueland, and Per E. Lønning
J Natl Cancer Inst 2004 96: 884. [Extract] [Full Text] [PDF]

RESPONSE: Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
Vered Stearns, Michael D. Johnson, James M. Rae, Antonella Novielli, Pankaj Bhargava, Daniel F. Hayes, Zeruesenay Desta, and David A. Flockhart
J Natl Cancer Inst 2004 96: 884-885. [Extract] [Full Text] [PDF]